The scrip ended 6.91 per cent up at Rs 627.80 on the BSE. During the day, it surged 8 per cent to touch Rs 634.80. Ranbaxy stock rose 4.90 per cent to Rs 467.
On the NSE, Sun Pharma gained 6.78 per cent to settle at Rs 628.
The stock was the best performer among the blue-chips on both the key indices -- Sensex and Nifty.
Sun Pharmaceutical Industries announced on Monday that it would acquire troubled rival Ranbaxy Laboratories in a USD 4-billion deal that includes USD 800 million debt. Sun's scrip that day had rallied nearly 3 per cent.
More From This Section
Both the companies have said that the merged entity will be the largest pharmaceutical firm in India, with combined revenue of about USD 4.2 billion. It will be the fifth-largest speciality generics company in the world.
Ranbaxy, controlled by Daiichi Sankyo of Japan, is struggling with quality compliance issues as all four of its plants in India have been banned by the US Food and Drug Administration from exporting products to America.
Sun's Karkhadi plant is also barred from shipping products to the US for violation of good manufacturing norms.